secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001628280-23-035790
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M
----------------------------------------------------------------------

- CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.
- Net loss $27.0M ($0.55 per share) vs $32.0M ($0.65) in Q3 2022; revenue $11.1M (up from $6.8M) from Roche and Biogen collaborations.
- Cash, equivalents and marketable securities $246.4M as of Sept 30, 2023; expected runway into H2 2025.
- CFT7455 Phase 1 dose escalation completed in monotherapy for R/R MM; combination arm continues; virtual event on Dec 12, 2023.
- Kendra Adams appointed CFO in September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/0001628280-23-035790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/cccc-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-035790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer